 | • レポートコード：MRC2303I0143 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の勃起不全治療薬市場規模が、予測期間中に年平均3.8%で成長すると予測しています。本レポートは、勃起不全治療薬の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（バイアグラ、シアリス、レビトラ/スタキシン、ステンドラ/スペドラ、その他）分析、流通チャンネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Apricus Biosciences Inc.、Bayer AG、Eli Lilly and Company、GlaxoSmithKline PLC、Petros Pharmaceutical、Pfizer Inc.、S.K. Chemicals Co. Ltd、Teva Pharmaceutical Industries Ltd、VIVUS Inc.、Lupin Limited、Glenmark Pharmaceuticals Limited、Cipla Ltdなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の勃起不全治療薬市場規模：製品別 - バイアグラの市場規模 - シアリスの市場規模 - レビトラ/スタキシンの市場規模 - ステンドラ/スペドラの市場規模 - その他製品の市場規模 ・世界の勃起不全治療薬市場規模：流通チャンネル別 - 病院薬局チャンネルの市場規模 - 小売薬局チャンネルの市場規模 - オンライン薬局チャンネルの市場規模 ・世界の勃起不全治療薬市場規模：地域別 - 北米の勃起不全治療薬市場規模 アメリカの勃起不全治療薬市場規模 カナダの勃起不全治療薬市場規模 メキシコの勃起不全治療薬市場規模 … - ヨーロッパの勃起不全治療薬市場規模 ドイツの勃起不全治療薬市場規模 イギリスの勃起不全治療薬市場規模 フランスの勃起不全治療薬市場規模 … - アジア太平洋の勃起不全治療薬市場規模 中国の勃起不全治療薬市場規模 日本の勃起不全治療薬市場規模 インドの勃起不全治療薬市場規模 … - 中東/南米の勃起不全治療薬市場規模 南アフリカの勃起不全治療薬市場規模 ブラジルの勃起不全治療薬市場規模 アルゼンチンの勃起不全治療薬市場規模 … - その他地域の勃起不全治療薬市場規模 ・競争状況 ・市場機会・将来の動向 |
The erectile dysfunction drugs market is expected to register a CAGR of nearly 3.8% during the forecast period.
With the rising prevalence of erectile dysfunction during the COVID-19 pandemic, the global erectile dysfunction drugs market is expected to grow rapidly during the forecast period. The research, led by Emmanuele A. Jannini, MD, professor of endocrinology and medical sexology at the University of Rome Tor Vergata in Rome, Italy, was published in the journal Andrology in March 2020. COVID-19 is more than five times more common in men with ED. The estimated risk of developing ED was 5.66 times higher in men with a history of COVID-19. Thus, the COVID-19 pandemic had a significant impact on the erectile dysfunction drugs market.
Some factors that drive the erectile dysfunction (ED) drugs market include the adoption of a sedentary lifestyle and its associated stress, the rising geriatric population, and the comorbidity between erectile dysfunction and heart disease and diabetes. A sedentary lifestyle, alcoholism, and smoking greatly increase the risk of erectile dysfunction. Increased acceptance of such negative lifestyle decisions may drive the market growth. According to the study published in the BMC Endocrine Disorders in July 2021, titled “Erectile dysfunction and associated factors among diabetic patients at, Hawassa, Southern, Ethiopia”, alcohol consumption, poor glycemic control, age, and diabetes duration were all found to be predictors of erectile dysfunction. Erectile dysfunction was found to be prevalent in 72.2% of people. After controlling all other variables, old age, diabetes duration, alcohol consumption, and poor glycemic control were found to have a significant relationship with erectile dysfunction.
Erectile dysfunction is the most common risk factor in men, and its incidence increases with age. Aging and older men frequently have comorbidities, like diabetes mellitus, chronic obstructive pulmonary disease, hypertension, cardiovascular diseases, etc.; likewise, they concurrently refer to a clinician for impairments in sexual function, mostly for erectile dysfunction (ED). For instance, according to the article published in the National Institutes of Health in June 2021, titled “Sexual Dysfunction in Diabetes”, sexual dysfunctions are common in people with diabetes and may arise from a variety of vascular, neurologic, and hormonal derangements.
The rise in the number of ED cases is often correlated with the high growth of obesity, diabetes, and cardiovascular disorders. Hypertension is additionally another major illness linked to male erectile dysfunction. As reported by the World Health Organization in 2021, the prevalence of hypertension has grown at a substantial rate; an estimated 1.28 billion adults aged 30 to 79 worldwide have been affected by hypertension, with the majority (two-thirds) living in low- and middle-income countries.
However, the patients are reluctant to seek treatment, and this factor is restraining the market growth.
Erectile Dysfunction Drugs Market Trends
The Viagra (sildenafil citrate) Segment is Expected to Dominate the Market
Erectile dysfunction is treated with the drug sildenafil. It helps men get an erection by increasing blood flow to the penis. After taking it, at least two-thirds of men reported improved erections.
Sildenafil, sold in the brand name Viagra, among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. Its effectiveness in treating sexual dysfunction in women has not been demonstrated. Sildenafil (Viagra) is the most common drug used as first-line therapy in the treatment of erectile dysfunction.
Sildenafil (Viagra) is the most effective when taken on an empty stomach one hour before sex. It is effective for four to five hours or more if you have mild to moderate erectile dysfunction. In March 2019, Lupin received approval for its Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer Inc.’s Viagra Tablets, 25 mg, 50 mg, and 100 mg.
Thus, the effectiveness of Viagra (sildenafil citrate) in the treatment of erectile dysfunction is expected to boost the segment over the forecast period.
North America is Expected to Dominate the Market
North America is expected to dominate the erectile dysfunction drugs market, owing to the rising geriatric population, increase in cases of ED, and the presence of better healthcare infrastructure. According to the article published by Rural Health Information Hub in April 2019, in the United States, there are more than 46 million older adults aged 65 and above; by 2050, that number is expected to rise to nearly 90 million. The number of older adults is expected to rise by nearly 18 million between 2020 and 2030 when the last of the baby boom cohorts reach the age of 65. The rise in the geriatric men’s population is expected to increase the number of patients suffering from ED, as it is very common in men above the age of 40. The availability of various ED drugs through over-the-counter (OTC) and online channels is a key factor for the dominance of this region.
As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2021, in the United States, approximately 30 million men suffer from ED. The United States has the highest rate of self-reported ED, increasing the prevalence of ED, which is expected to drive the market growth over the forecast period.
There are some companies making advancements in terms of the time taken by patients to take the pill before sexual activity. For instance, in March 2019, Dr. Reddy’s Laboratories launched Tadalafil tablets used to treat erectile dysfunction in the US market. The approved product is a therapeutic equivalent generic version of Cialis (tadalafil) tablets. These tablets are available in four strengths, including 2.5 mg, 5 mg, 10 mg, and 20 mg, each in 30-count bottle sizes. In the case of the United States, several companies collaborate with domestic players having extensive market shares in the country. Thus, companies get exclusive rights for marketing, which benefits this market significantly.
The increasing geriatric population in the country and increasing product launches boost the market in the region.
Erectile Dysfunction Drugs Market Competitor Analysis
The market is fragmented due to the presence of various small and large market players. Some of the market players are Apricus Biosciences Inc., Bayer AG, Eli Lilly and Company, Ferring Pharmaceuticals, GlaxoSmithKline PLC, Metuchen Pharmaceuticals LLC, S.K. Chemicals Co. Ltd, Teva Pharmaceutical Industries Ltd, and VIVUS Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Defination
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Adoption of a Sedentary Lifestyle Along with the Associated Stress
4.2.2 Rising Geriatric Population
4.2.3 Comorbidity between Erectile Dysfunction and Heart Diseases and Diabetes
4.3 Market Restraints
4.3.1 Reluctance of Patients to Seek Treatment
4.3.2 Poor Patient Adherence to ED Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size in USD million)
5.1 Product
5.1.1 Viagra (sildenafil citrate)
5.1.2 Cialis (Tadalafil)
5.1.3 Levitra/Staxyn (vardenafil)
5.1.4 Stendra/Spedra (avanafil)
5.1.5 Zydena (udenafil)
5.1.6 Vitaros (Alprostadil Cream)
5.1.7 Other Products
5.2 Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Online Pharmacies
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Apricus Biosciences Inc.
6.1.2 Bayer AG
6.1.3 Eli Lilly and Company
6.1.4 GlaxoSmithKline PLC
6.1.5 Petros Pharmaceutical
6.1.6 Pfizer Inc.
6.1.7 S.K. Chemicals Co. Ltd
6.1.8 Teva Pharmaceutical Industries Ltd
6.1.9 VIVUS Inc.
6.1.10 Lupin Limited
6.1.11 Glenmark Pharmaceuticals Limited
6.1.12 Cipla Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS